Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's Dividend Payout Ratio is ranked worse than 58.43% of 445
companies
in the Drug Manufacturers industry
Industry Median: 0.38
vs CAI:PHAR: 0.44
During the past 12 months, Egyptian International Pharmaceutical Investments's average Dividends Per Share Growth Rate was 50.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -4.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -11.50% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was -0.30% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Egyptian International Pharmaceutical Investments was 44.30% per year. The lowest was -21.10% per year. And the median was 5.80% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Egyptian International Pharmaceutical Investments (CAI:PHAR) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Egyptian International Pharmaceutical Investments Dividend Payout Ratio Related Terms
Egyptian International Pharmaceutical Investments Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Dividend Payout Ratio Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Dividend Payout Ratio vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Over the past decade, Egyptian International Pharmaceutical Investments' Dividend Payout Ratio has ranged from 0.26 to 0.81. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #260 out of 445 companies in the Drug Manufacturers industry, placing it in the top 58.4%.
Is Egyptian International Pharmaceutical Investments' Dividend Payout Ratio too high?
Egyptian International Pharmaceutical Investments' current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.81. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #260 out of 445 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #260 out of 445 companies for Dividend Payout Ratio. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, Egyptian International Pharmaceutical Investments' own Dividend Payout Ratio has ranged from 0.26 to 0.81 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.82, compared to a current price of E£85.80 — trading 43.4% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£85.80 is trading 43.4% above its estimated GF Value™ of E£59.82.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Dividend Payout Ratio: 0.00
GF Value™: E£59.82 vs. price of E£85.80 (43.4% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
